It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag

This is not an exhaustive list!

OncoAlert @danafarber Dana-Farber_GU

#OnwardFor2024

I had a chance to talk at ASCO Connection about myself, my unusual career path coming from 🇲🇽, and the impact that mentorship has had on my professional development.

Special thanks to ASCOTECAG for the opportunity to share my story!

connection.asco.org/magazine/featu…

Part 2 TwoOncDocs on Metastatic Bladder Cancer in collaboration w/ Uromigos is out today w/ key pearls on Tx, toxicities, variant histologies, UTUC Brian Rini, MD, Tom Powles discusses #EV302 & learns what the boards are

open.spotify.com/episode/676npA…

Big news for bladder cancer in US!
“On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (la/mUC).”

👏 to Toni Choueiri, MD Brian Rini, MD Laurence Albiges for +ve FDA for belzutifan in IO/VEGF pretreated RCC based on +ve PFS not OS (yet). All other TKIs approved without OS btw(except Cabo).The ⬆️ RR/QOL makes it good in 3rd line. It’s best earlier and in combination? bit.ly/3v1NSa3

FYI — STRONGLY recommend listening to TwoOncDocs podcast! I started far too late but it would be a great tool during fellowship to get an overview and then quick recap with HY info for boards. Great job Karine Tawagi MD Samantha Armstrong!!

We are so honored to have special guests Brian Rini, MD Tom Powles from Uromigos on this week’s episode of TwoOncDocs!

We cover high yield facts for trainees & clinical pearls on Localized Bladder CA (NMBIC, NAC, adjuvant, TMT) (& a s/o to Petros Grivas)

shorturl.at/jnE47

One of the most resonating pieces I’ve read this year.

Trainees & early-career folks, a must read! 👇🏼

ASCO TECAG Fernando Diaz, MD Rafeh Naqash, MD Hem-Onc Fellows Network Ana I. Velázquez Mañana, MD MSc (she/her/ella) Nazli Dizman Karine Tawagi MD @ASCO

We are so excited this collaboration with ASCO is out - discussing LuPSMA approvals, trials, resistance/challenges & future directions - at the same time that we finally have LuPSMA available for our patients w/ #prostatecancer at UIC

dailynews.ascopubs.org/do/psma-target…

LuPSMA was a game-changer in #mCRPC , but questions remain regarding optimal dosing strategies, possible causes of resistance, and access issues that limit therapeutic options: brnw.ch/21wF7Wx #ASCODailyNews Karine Tawagi MD University of Illinois Cancer Center #pcsm

Great news today 👉Breakthrough Therapy Designation for TAR200🥨based on results of SunRISe-1 for potential future treatment of patients with BCG unresponsive HR- #NMIBC , ineligible for RC/decided not to undergo RC #BladderCancer #MyCompany J&J Innovative Medicine
👉prnewswire.com/news-releases/…

(1/2) Our latest paper on the efficacy of contemporary TT after patients with sarcomatoid and/or rhabdoid dediff progress on ICT shorturl.at/ptG14 Pavlos Msaouel The Oncologist In 57 patients, median time on TT was 6.4 m and ORR was 20%

⭐️Outstanding ESMO 2023 Kidney and Bladder cancer discussion by Dr. Karine Tawagi at the 2023 Updates in Cancer Treatments Karine Tawagi MD hosted by Edgardo.S.Santos.MD.FACP and Dr. Luis E. Raez in Miami. Pedro C Barata, MD MSc FACP Alan Tan The Medical Educator Consortium FLASCO Sylvester Comprehensive Cancer Center TwoOncDocs

I would like to share the story of how a patient with cancer came up with the idea for a randomized trial, & how listening to him saved a lot of lives.

1/ In 2002, I had just completed a randomized trial with the notorious drug thalidomide for the cancer, multiple myeloma.

Thanks to all that attended our first #GUROUNDS Chicago last night. Randy Sweis Sirisha Tummala Karine Tawagi MD Kunal Desai MD MBA MS Natalie Reizine Neha Hippalgaonkar did an amazing job presenting important GU updates! UChicagoCancerCenter RUSH Heme/Onc University of Illinois College of Medicine

GU superstars in the Windy Cindy reviewing the latest in Bladder, Kidney and Prostate Cancer! Alan Tan Randy Sweis Karine Tawagi MD and Natalie Reizine!

Our first GU rounds is hours away, tonight at the Ivy Room. We have a packed agenda with Randy Sweis Karine Tawagi MD Sirisha Tummala Natalie Reizine. Virtual attendees welcome. Register at gurounds.com

Congrats to all those matching into Heme/Onc fellowship today!! 🎉 Welcome to the club 😊

We will be back next week with a review on Follicular Lymphoma then we will have some exciting Bladder CA updates to round out December with very special guests! Hem-Onc Fellows Network ASCO TECAG

ASCO TECAG Ana I. Velázquez Mañana, MD MSc (she/her/ella) Fernando Diaz, MD Hem-Onc Fellows Network Arthi Sridhar Aakash Desai, MD, MPH Sam Brondfield, MD, MAEd OncMedEdCoP Maya Abdallah @ASCO Resources I used:
1) Hemeoncquestions.com (throughout fellowship)
2) MDA board review video series (6-8 weeks before boards)
3) ASCO SEP Q bank (2-3 weeks from exam)
4) #OncTwitter (throughout training)
5) TwoOncDocs (2 weeks before boards, especially on the treadmill)

Treatment for muscle invasive bladder cancer will change if the ongoing R3s are +ve. Neoadjuvant IO/ADC combination, bladder sparing approaches, intravesical therapy (TAR200) & ctDNA will improve outcomes and spare patients unnecessary treatments. This is the next chapter IMO.